JP2022108241A5 - - Google Patents

Download PDF

Info

Publication number
JP2022108241A5
JP2022108241A5 JP2021055886A JP2021055886A JP2022108241A5 JP 2022108241 A5 JP2022108241 A5 JP 2022108241A5 JP 2021055886 A JP2021055886 A JP 2021055886A JP 2021055886 A JP2021055886 A JP 2021055886A JP 2022108241 A5 JP2022108241 A5 JP 2022108241A5
Authority
JP
Japan
Prior art keywords
alkyl
tautomer
compound
occurrence
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021055886A
Other languages
English (en)
Japanese (ja)
Other versions
JP7611045B2 (ja
JP2022108241A (ja
Filing date
Publication date
Priority claimed from PCT/CN2021/071256 external-priority patent/WO2022150962A1/en
Application filed filed Critical
Publication of JP2022108241A publication Critical patent/JP2022108241A/ja
Publication of JP2022108241A5 publication Critical patent/JP2022108241A5/ja
Application granted granted Critical
Publication of JP7611045B2 publication Critical patent/JP7611045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021055886A 2021-01-12 2021-03-29 プロテアーゼ阻害剤、その調製、および使用 Active JP7611045B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/071256 2021-01-12
PCT/CN2021/071256 WO2022150962A1 (en) 2021-01-12 2021-01-12 Protease inhibitors, preparation, and uses thereof

Publications (3)

Publication Number Publication Date
JP2022108241A JP2022108241A (ja) 2022-07-25
JP2022108241A5 true JP2022108241A5 (https=) 2022-09-20
JP7611045B2 JP7611045B2 (ja) 2025-01-09

Family

ID=75277880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021055886A Active JP7611045B2 (ja) 2021-01-12 2021-03-29 プロテアーゼ阻害剤、その調製、および使用

Country Status (5)

Country Link
US (1) US11958830B2 (https=)
EP (1) EP4026830A1 (https=)
JP (1) JP7611045B2 (https=)
CN (2) CN113072497B (https=)
WO (1) WO2022150962A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3089678A1 (en) 2018-01-31 2019-08-08 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2019243315A1 (en) 2018-06-21 2019-12-26 Heparegenix Gmbh Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11912701B2 (en) 2018-07-16 2024-02-27 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AU2021207236A1 (en) 2020-01-15 2022-08-11 Heparegenix Gmbh 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases
JP2024178473A (ja) * 2021-09-03 2024-12-25 塩野義製薬株式会社 ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
US20250042889A1 (en) 2021-09-07 2025-02-06 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. 3clpro protease inhibitor
TW202408511A (zh) 2022-08-05 2024-03-01 美商基利科學股份有限公司 Sars-cov2主蛋白酶抑制劑
US20240158368A1 (en) 2022-10-14 2024-05-16 Abbvie Inc. Pyrrolidine Main Protease Inhibitors as Antiviral Agents
WO2024124287A1 (en) * 2022-12-12 2024-06-20 The Walter And Eliza Hall Institute Of Medical Research Compounds for treating viral infection
WO2024183629A1 (zh) * 2023-03-03 2024-09-12 齐鲁动物保健品有限公司 3CLpro蛋白酶抑制剂在制备治疗猫冠状病毒疾病药物中的用途
EP4695230A1 (en) * 2023-04-11 2026-02-18 Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Protease inhibitors and uses thereof
EP4722196A1 (en) 2023-05-31 2026-04-08 Westlake Pharmaceuticals (Hangzhou) Co., Ltd. Crystal of viral protease inhibitor and use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US6335350B1 (en) * 1998-12-09 2002-01-01 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
PL348178A1 (en) * 1998-12-09 2002-05-06 American Home Prod Thiourea inhibitors of herpes viruses
EP1137633A2 (en) * 1998-12-09 2001-10-04 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
TW200306159A (en) 2002-03-19 2003-11-16 Du Pont Bicyclic fused pyridinyl amides and advantageous compositions thereof for use as fungicides
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7067529B2 (en) 2003-05-19 2006-06-27 Hoffmann-La Roche Inc. Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors
US7495011B2 (en) * 2003-07-15 2009-02-24 Arigen Pharmaceuticals, Inc. Anti-coronavirus drug
US7732446B1 (en) * 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2597446A1 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP2124568A1 (en) * 2007-01-17 2009-12-02 Merck & Co., Inc. Decahydroquinoline analogs as cb2 receptor modulators
CN101519372B (zh) * 2009-04-01 2011-07-20 深圳市盛捷生物技术有限公司 用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
US20130131018A1 (en) * 2010-06-04 2013-05-23 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2012090177A2 (en) * 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
RU2014133390A (ru) 2012-01-30 2016-03-20 Ф. Хоффманн-Ля Рош Аг Производные изохинолина и нафтиридина
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
IN2014MN01982A (https=) * 2012-04-25 2015-07-10 Raqualia Pharma Inc
WO2014025651A1 (en) * 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
SI2953941T1 (sl) 2013-02-11 2017-08-31 Constellation Pharmaceuticals, Inc. Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR101715090B1 (ko) * 2013-08-28 2017-03-13 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
KR20150027922A (ko) * 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
WO2016036638A1 (en) * 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
KR102764027B1 (ko) * 2015-10-15 2025-02-07 코넬 유니버시티 프로테아좀 억제제 및 이의 용도
WO2018002848A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
CN107674029A (zh) * 2016-08-02 2018-02-09 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
US11247970B2 (en) * 2017-03-22 2022-02-15 Dana-Farber Cancer Institute, Inc. Selective inhibition of gluconeogenic activity
EP3829719B1 (en) * 2018-07-27 2025-04-02 Cocrystal Pharma, Inc. Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
EP3856178B1 (en) 2018-09-28 2026-03-11 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators
EP3982954A4 (en) * 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA

Similar Documents

Publication Publication Date Title
JP2022108241A5 (https=)
RU2012153164A (ru) Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути
JP2004500426A5 (https=)
ME00354B (me) Novi lekovi za tretiranje hronićnog opstruktivnog oboljenja pluća
BRPI0212894B1 (pt) Composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
RU97116714A (ru) Композиция селективных ингибиторов вирусных или бактериальных нейраминидаз (варианты), способ лечения или профилактики заболевания гриппом, способ лечения или профилактики вирусных заболевания (варианты)
RU2005123802A (ru) Производные адамантана, способы их получения и содержащие их фармацевтические композиции
JP2010501584A5 (https=)
JPH08510479A (ja) 眼の炎症障害を処置するための3‐ベンゾイルフェニル酢酸誘導体を含む局所的に投与可能な組成物
JP2008531479A5 (https=)
ATE188871T1 (de) Verfahren zur behandlung von viralen infectionen
JP2022137237A5 (https=)
JP2021525787A5 (https=)
JPWO2022251502A5 (https=)
PL118755B1 (en) Process for preparing novel derivatives of phenethanolamine
JP2014511897A5 (https=)
JPS63502179A (ja) 新規なアリ−ル誘導体類
GB1585963A (en) Aryl sulphur compounds
RU95114673A (ru) Производные алкилбензоилгуанидина
ES513177A0 (es) "un procedimiento para la preparacion de pirimidin-2-onas sustituidas".
JPWO2023072257A5 (https=)
JPH08512279A (ja) 抗サイトメガロウイルス剤としてのポリアミン誘導体類
JP2005506324A5 (https=)
JPWO2022020714A5 (https=)
JP2008519848A5 (https=)